Brain shuttle peptides: From permeability assay toolbox to data-driven discovery.
Getting peptides into the brain is a big deal. The blood-brain barrier (BBB) keeps most things out, but researchers are making progress with brain shuttle peptides. These short chains can cross the BBB and deliver research compounds right where they're needed. The new review from Mohović and colleagues lays out the latest tools and strategies for figuring out which peptides actually make the cut.
Adv Pharmacol
by Mohović N, Njirjak M, Dražić E et al.
“Brain shuttle peptides: From permeability assay toolbox to data-driven discovery. Mohović N(1), Njirjak M(2), Dražić E(2), Bevandić PJ(3), Kalafatovic D(4). Author information: (1)Faculty of Biotechnology and Drug Development, University of Rijeka, Rijeka, Croatia. (2)Faculty of Engineering, University of Rijeka, Rijeka, Croatia; Center for Artificial Intelligence and Cybersecurity, University of Rijeka, Rijeka, Croatia. (3)Faculty of Biotechnology and Drug Development, University of Rijeka, Rijeka, Croatia; Center for Artificial Intelligence and Cybersecurity, University of Rijeka, Rijeka, Croatia. Electronic address: patrizia.jankovicbevandic@jglpharma.com. (4)Faculty of Engineering, University of Rijeka, Rijeka, Croatia; Center for Artificial Intelligence and Cybersecurity, University of Rijeka, Rijeka, Croatia. Electronic address: daniela.kalafatovic@uniri.hr. The blood-brain barrier (BBB) is a highly selective transport interface that protects the central nervous system (CNS), but its complex cellular and molecular architecture presents a major challenge for drug delivery to the brain. Peptides have emerged as promising brain shuttles due to their selectivity, ease of synthesis, and ability to engage endogenous transport mechanisms such as receptor- or adsorptive-mediated transcytosis. We provide an overview of in vitro and in vivo models, ranging from artificial membranes, dynamic BBB-on-a-chip systems and mass-based quantification techniques to brain perfusion and molecular imaging. Particular emphasis is placed on how these approaches are selected and combined to assess BBB permeability, transport mechanisms, and brain distribution of peptide shuttles. Recently, machine learning methods have been increasingly used to identify peptide sequences with BBB-crossing potential. By highlighting recent examples and key methodological considerations, this chapter aims to guide researchers in selecting appropriate tools and strategies for studying peptide transport across the BBB. Copyright © 2026. Published by Elsevier Inc.”
The old approach? Test one peptide at a time. The new approach? Bring on the robots and the data. Researchers now use everything from basic artificial membranes to advanced BBB-on-a-chip systems. There’s even mass-based quantification and live molecular imaging to track peptides in action.
Highlights from the review:
Peptides can hitch a ride using the brain’s own transport systems. Think receptor- or adsorptive-mediated transcytosis.
In vitro models are getting more realistic. BBB-on-a-chip can simulate blood flow and cell barriers.
Quantification techniques let you measure exactly how much peptide gets through.
Molecular imaging shows where peptides go in the brain — in real time.
Machine learning is starting to predict which sequences will cross the BBB before you ever make them in the lab.
Key takeaway: Peptide research is finally catching up with modern tools. There’s a clear path for researchers to design, test, and optimize brain shuttle peptides much faster. If you’re in the field, it’s time to get familiar with these models and start thinking data-first. The review is a must-read for anyone building or testing new brain-targeted peptides. For more on peptide design and BBB delivery, check out the peptide research index. Want to start sourcing or testing your own sequences? The vendor directory is a solid place to begin. This is where peptide research gets interesting.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.